AbbVie Endocrine filed the lawsuit Nov. 6 in a Delaware court claiming Takeda either didn’t produce enough units of Lupron or is improperly giving the drug to other customers. Lupron is a drug used to treat prostate and breast cancer and endometriosis.
In June, U.S. health regulators said they found manufacturing problems at a Takeda plant in Hikari, Japan, that makes Lupron for the U.S. market, Bloomberg reported. The problems included flaws in procedures designed to prevent microbiological contamination of sterile drugs. Takeda said in an earnings release that resolving those problems caused a shortage of Lupron.
AbbVie said in a public filing that it wants damages from the supply agreement, Bloomberg reported.
Read the full article here.
More articles on pharmacy:
Eli Lilly’s COVID-19 antibody drug gets FDA emergency approval
Pfizer’s COVID-19 vaccine prevents 90% of infections, interim trial analysis finds
Some Operation Warp Speed 3rd-party contracts lack consumer protections, HHS release shows
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.